Articles On Cynata Therapeutics (ASX:CYP)
Title | Source | Codes | Date |
---|---|---|---|
Scott Power: The lowdown on Sonic’s $700m German excursion
Sonic Healthcare to buy LADR – Laboratory Group Dr. Kramer & Colleagues in Germany for ~A$700 million ASX health stocks fall 2.3% over past five days, while the broader market fell ~1.5% Chemist Warehouse could list on the ASX by earl... |
Stockhead | CYP | 1 week ago |
CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX:... |
FNArena | CYP | 2 weeks ago |
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns
The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX Paradigm Biopharmaceuticals rose 151% in Novembe... |
Stockhead | CYP | 2 weeks ago |
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th... |
Stockhead | CYP | 1 month ago |
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Healthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as Fed cuts rates How ASX biotechs performed in the month of September The S&P 500 Health Care Index, a key world benchmark for health... |
Stockhead | CYP | 2 months ago |
Alive and Kicking: Watch this space on controversy-free stem-cell therapy trials, says Cynata
Cynata Therapeutics flags three trial results in the short term for three different conditions, including diabetic leg ulcers Prescient Therapeutics prepares for a blood cancer trial and potential fast-track approval Pacific Edge chairman... |
Stockhead | CYP | 3 months ago |
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment The ASX Healthcare Index (AS... |
Stockhead | CYP | 3 months ago |
ASX Market Close: Index dips slightly as AMP soars | August 8, 2024
Volatility remained the status quo as the ASX200 ended down 0.23%. The local bourse briefly touched into the green after lunch, but the mood was short-lived. The market almost immediately pared gains, sinking back into the red. There... |
themarketonline.com.au | CYP | 4 months ago |
Closing Bell: Markets still bumpy as ASX drops again; Qantas admits board made mistakes
The ASX dropped, dragged down by Real Estate and Mining stocks Qantas cuts former CEO’s compensation by $9.3m Fears of a US recession are growing, with the Sahm Rule signalling potential trouble A selloff in Real Estate and Mining stock... |
Stockhead | CYP | 4 months ago |
Cynata study shows efficacy of stem-cell therapy on chronic lung disease
Cynata Therapeutics Ltd (ASX:CYP) has seen its share price rise more than 10% on the release of a study indicating the potential for Cymerus – its ‘off the shelf’ therapeutic stem cell platform technology – to reverse pulmonary fibrosis and... |
themarketonline.com.au | CYP | 4 months ago |
Stocks of the Hour: NOVONIX, Cynata Therapeutics, Cauldron Energy
To register for Friday's webinar click here. NOVONIX (ASX:NVX) and CBMM has joined forces to develop cost-effective, high-performance cathode materials. NOVONIX's patented process will combine with CBMM's niobium to create high-performanc... |
ShareCafe | CYP | 4 months ago |
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month
S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July The S&P/ASX 200 Health Care index [XHJ]... |
Stockhead | CYP | 4 months ago |
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month In a major blow for... |
Stockhead | CYP | 4 months ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | CYP | 5 months ago |
ASX Health Stocks: Imricor installs key equipment at Swiss hospital
Imricor completes installation of iCMR capital equipment at Lausanne University Hospital in Switzerland PYC Therapeutics says safety data from patient cohort four successfully reviewed with recommendation trial continues Cynata Therapeutic... |
Stockhead | CYP | 5 months ago |
Closing Bell: ASX rallies as RBA considers hiking rates; Bitcoin ETF to start trading on Thursday
ASX rose as the RBA held interest rates at 12-year high 4.35pc All 11 sectors on the ASX gained, with significant moves from Pilbara and Fortescue ASX to launch first bitcoin-linked ETF on Thursday Aussie stocks bounced back by +0.8%... |
Stockhead | CYP | 6 months ago |
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month The S&P/ASX 200 Health Care [XHJ] closed flattish for the month o... |
Stockhead | CYP | 6 months ago |
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners
Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month The phrase ‘you are what you eat’ was coined almost a c... |
Stockhead | CYP | 7 months ago |
From high-tech cancer fighters to AI-wielding crime busters, these are some of the most innovative firms on the ASX
Special Report: A recent lunch put together in Sydney by Jane Morgan Management and Éthica Capital saw a number of the ASX’s most innovative biotech and tech companies present and pitch to an audience of potential investors on the lookout f... |
Stockhead | CYP | 7 months ago |
Hot Money Monday: How momentum traders use Relative Strength Index to identify entry and exit points
Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. The strategy makes a calculated bet that the stock market’s recent winners will remain winners. The Relative Strength Index (RSI) is a popular... |
Stockhead | CYP | 7 months ago |
Up close and personal with ASX tech and Biotech
Investors got the chance to get up close and personal with ASX technology and biotech companies in Sydney recently at the JMM & Ethica Capital Innovation & Investment Insights Lunch. Featuring quick ‘stand up and pitch your story’ s... |
Stockhead | CYP | 7 months ago |
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | CYP | 7 months ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | CYP | 7 months ago |
Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial
MELBOURNE, Australia, April 8, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of pati... |
FNArena | CYP | 8 months ago |
Cynata wins EU ethics approval for phase 2 Trial of CYP-001
Biotech company Cynata Therapeutics (ASX:CYP) received regulatory and ethics approval in the European Union (EU) for its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). CYP-001 is Cynata’s innovati... |
themarketonline.com.au | CYP | 9 months ago |
Closing Bell: ASX a little lower after hosting a Big 4 bank midweek spank
Local markets end lower on big bank sell-off Material gains offset by Telco’s and Financials Small Caps led by rare earths developer Arafura Local markets have not showered anyone in glory, profit or confidence on Thursday. At 4pm on T... |
Stockhead | CYP | 9 months ago |
Cynata Therapeutics’ breakthrough in regenerative medicine
Peter Milios: I am Peter Milios from the Finance News Network, and today I am talking with Cynata Therapeutics. Cynata is a clinical stage stem cell and regenerative medicine company. Their ASX code is CYP and they have a market cap of ar... |
ShareCafe | CYP | 9 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | CYP | 9 months ago |
Cynata Therapeutics advances Phase 2 trial for high-risk aGvHD treatment
Cynata Therapeutics’ (ASX:CYP) announces the enrolment and treatment of the first participant (CYP-001) in its Phase 2 clinical trial for high-risk acute graft versus host disease (aGvHD) US FDA has granted clearance for an Investigation... |
themarketonline.com.au | CYP | 9 months ago |
First Patient Treated in Phase 2 GvHD Trial
MELBOURNE, Australia, March 5, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enro... |
FNArena | CYP | 9 months ago |
ASX Health Stocks: Healius rips higher as new CEO takes over; Nova Eye bags record US sales
Healius has new CEO Nove Eye reports record US sales in February Cynata says first patient has been enrolled in Phase 2 trial Healius has a new CEO, shares rip higher Healius (ASX:HLS) jumped 14% this morning after announcing that it wo... |
Stockhead | CYP | 9 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | CYP | 9 months ago |
Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial
MELBOURNE, Australia, Feb. 26, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surfa... |
FNArena | CYP | 9 months ago |
ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns
Recce Pharma says Phase 1/2 study is achieving primary endpoints Cynata also reports also reports good progress in Phase 1 Cardiex is back on the ASX! Recce to expand diabetes foot ulcer Phase 1/2 trial An independent Safety Committee h... |
Stockhead | CYP | 9 months ago |
Closing Bell: ASX phones in more gains as prices plunge in Beijing and records tumble in New York
ASX200 trims gains to end circa 0.3pc higher Sectors in the money include Utilities and IT Small cap winners led by Alliance Nickel and Sarytogan Graphite A fresh batch of fat Q4 profit reports in the US overnight was apparently all t... |
Stockhead | CYP | 10 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | CYP | 1 year ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | CYP | 1 year ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | CYP | 1 year ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | CYP | 1 year ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | CYP | 1 year ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | CYP | 1 year ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | CYP | 1 year ago |
ASX Health Stocks: Althea says its cannabis beverage could generate $5m of sales in Canada
Althea extends contract in Canada Clarity moves forward to cohort 3 Cynata opens Phase 2 recruitment Althea extends deal in Canada for cannabis drinks Cannabis company Althea Group (ASX:AGH) announced that its wholly owned subsidiary, P... |
Stockhead | CYP | 1 year ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | CYP | 1 year ago |
ASX Health Stocks: Medibio jumps 50pc on Phase 1 results; Cann doubles cannabis harvest
Medibio jumps after completing Phase 1 clinical trial Cann Group’s latest crop harvest is at a scale twice that of previous harvests 4DMedical wins a $1.1 million from the Fed government Microcap Medibio (ASX:MEB) jumped 50% this mornin... |
Stockhead | CYP | 1 year ago |
Dr Boreham’s Crucible: Is this a case of what’s good for Mesoblast is good for Cynata?
The changing of the guard is not just evident at Buckingham Palace: barely a week goes by without an ASX-listed biotech announcing a new person at the helm. In the case of the junior stem-cell therapy developer Cynata (ASX:CYP), incumbent D... |
Stockhead | CYP | 1 year ago |
CLOSING BELL: Another red day on the ASX as Fed eyes ‘mild recession’ and big miners dip
S&P/ASX 200 closes well in the red today: -1.24% after US stocks dipped on the back of Fed hawkishness Sectors-wise, IT was the only group finishing vaguely in the green, with Materials Discretionary and Financials stocks largely hamm... |
Stockhead | CYP | 1 year ago |
Cynata Therapeutics announces CEO succession and board changes
Australian clinical-stage cell therapy company Cynata Therapeutics (ASX:CYP) has announced the appointment of Dr Kilian Kelly as its new CEO and managing director. |
BiotechDispatch | CYP | 1 year ago |
TMH Market Close: ASX200 closes the financial year in the green
The ASX200 closed the 2023 financial year marginally higher, ahead of significant Labor Government changes coming into effect from tomorrow. Workers on the minimum wage will be paid nearly six per cent more per hour, while employer’s sup... |
themarketherald.com.au | CYP | 1 year ago |
Cynata Therapeutics (AX:CYP) announces CEO succession and board changes
Cynata Therapeutics (CYP) appoints Dr Kilian Kelly as its CEO and Managing Director, effective July 1 Dr Kelly has held the role of CYP Chief Operating Officer since May 2019 and has been “instrumental” in advancing the company’s clinica... |
themarketherald.com.au | CYP | 1 year ago |